Mary Slatter

Mary Slatter

Auto-generated profile, based on publicly available information

Mary Slatter

Great North Children's Hospital, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2011 in Blood
Verified
Journal Article
Closed access
PDF file
MSMary A. Slatter
Mary A. Slatter
KRKanchan Rao
Kanchan Rao
PAPersis Amrolia
Persis Amrolia
TFTerry Flood
Terry Flood
MAMario Abinun
Mario Abinun
PVPaul Veys
Paul Veys
Children with primary immunodeficiency diseases, particularly those less than 1 year of age, experience significant toxicity after hematopoietic stem cell transplantation, with busulfan- or melphalan-based conditioning. Treosulfan causes less veno-occlusive disease than busulfan and does not require pharmacokinetic monitoring. We report its use in 70 children. Children received 42 g/m2 or 36 g/m2 with cyclophosphamide 200 mg/kg (n = 30) or fludarabine 150 mg/m2 (n = 40), with alemtuzumab in most. Median age at transplantation was 8.5 months (range, 1.2-175 months); 46 (66%) patients were 12 months of age or younger. Donors were as follows: matched sibling donor, 8; matched family donor, 13; haploidentical, 4; and unrelated, 45. Median follow-up was 19 months (range, 1-47 months). Overall survival was 81%, equivalent in those age less or greater than 1 year. Skin toxicity was common. Veno-occlusive disease occurred twice with cyclophosphamide. Eighteen patients (26%) had graft-versus-host disease, and only 7 (10%) greater than grade 2. Two patients rejected; 24 of 42 more than 1 year after transplantation had 100% donor chimerism. The remainder had stable mixed chimerism. T-cell chimerism was significantly better with fludarabine. Long-term follow-up is required, but in combination with fludarabine, treosulfan is a good choice of conditioning for hematopoietic stem cell transplantation in primary immunodeficiency disease.

1 August 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MSMary A. Slatter
Mary A. Slatter
KEKarin R. Engelhardt
Karin R. Engelhardt
LBLauri M. Burroughs
Lauri M. Burroughs
PAPeter D. Arkwright
Peter D. Arkwright
ZNZohreh Nademi
Zohreh Nademi
TTTroy R. Torgerson
Troy R. Torgerson


1 March 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MSMary A. Slatter
Mary A. Slatter
KRKanchan Rao
Kanchan Rao
IHIntan Juliana Abd Hamid
Intan Juliana Abd Hamid
ZNZohreh Nademi
Zohreh Nademi
RCRobert Chiesa
Robert Chiesa
PVPaul Veys
Paul Veys
We previously published results for 70 children who received conditioning with treosulfan and cyclophosphamide (n = 30) or fludarabine (n = 40) before undergoing hematopoietic stem cell transplantation (HSCT) for primary immunodeficiency (PID). Toxicity was lower and T cell chimerism was better in the patients receiving fludarabine, but cohort numbers were relatively small and follow-up was short. Here we report outcomes of 160 children who received homogeneous conditioning with treosulfan, fludarabine, and, in most cases, alemtuzumab (n = 124). The median age at transplantation was 1.36 years (range, .09 to 18.25 years). Donors included 73 matched unrelated, 54 1 to 3 antigen-mismatched unrelated, 12 matched sibling, 17 other matched family, and 4 haploidentical donors. Stem cell source was peripheral blood stem cells (PBSCs) in 70, bone marrow in 49, and cord blood in 41. Median duration of follow-up was 4.3 years (range, .8 to 9.4 years). Overall survival was 83%. No patients had veno-occlusive disease. Seventy-four patients (46%) had acute GVHD, but only 14 (9%) greater than grade II. Four patients underwent successful retransplantation for graft loss or poor immune reconstitution. Another patient experienced graft rejection and died. There was no association between T cell chimerism >95% and stem cell source, but a significant association was seen between myeloid chimerism >95% and use of PBSCs without an increased risk of significant GVHD compared with other sources. All 11 patients with severe combined immunodeficiency diagnosed at birth were alive at up to 8.7 years of follow-up. Long-term studies are needed to determine late gonadotoxic effects, and pharmacokinetic studies are needed to identify whether specific targeting is advantageous. The combination of treosulfan, fludarabine, and alemtuzumab is associated with excellent results in HSCT for PID.

16 May 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJarmila Stremenova Spegarova
Jarmila Stremenova Spegarova
PSPraisoody Sinnappurajar
Praisoody Sinnappurajar
DJDalila Al Julandani
Dalila Al Julandani
RNRokas Navickas
Rokas Navickas
HGHelen Griffin
Helen Griffin
SHSophie Hambleton
Sophie Hambleton
A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant

5 April 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
MSMary Slatter
Mary Slatter
SLSu Han Lum
Su Han Lum
Patients with inborn errors of immunity (IEI) have been transplanted for more than 50 years. Many long-term survivors have ongoing medical issues showing the need for further improvements in how hematopoietic stem cell transplantation (HSCT) is performed if patients in the future are to have a normal quality of life. Precise genetic diagnosis enables early treatment before recurrent infection, autoimmunity and organ impairment occur. Newborn screening for severe combined immunodeficiency (SCID) is established in many countries. For newly described disorders the decision to transplant is not straight-forward. Specific biologic therapies are effective for some diseases and can be used as a bridge to HSCT to improve outcome. Developments in reduced toxicity conditioning and methods of T-cell depletion for mismatched donors have made transplant an option for all eligible patients. Further refinements in conditioning plus precise graft composition and additional cellular therapy are emerging as techniques to personalize the approach to HSCT for each patient